Letermovir (CMV prophylaxis after kidneytransplant) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Letermovir (Prophylaxe einer CMV-Erkrankung nach Nierentransplantation) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Letermovir (prophylaxis of CMV disease after kidneytransplant) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-137 Version: 1.0 Status: 7 Mar 2024 DOI: 10.60584/A23-137_en Extract of dossier assessment A23-137 Version 1.0 Letermovir ( prophylaxis of CMV disease after kidneytransplant) 7 Mar 2024 Institute
Preventing kidneytransplant failure by screening for antibodies against human leucocyte antigens followed by optimised immunosuppression: OuTSMART RCT Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology AssessmentProgramme Grants for Applied ResearchPublic Health ResearchTwitterFacebookLinkedInEmailHome >> Journals >> Efficacy and Mechanism Evaluation >> Volume 10 >> Issue 5ToolkitDownload report PDFDownload report documentsDisclosure of interestDownload report XMLCitation ToolsPrintResponses to this report (0)Permissions informationVIEW PROJECTPreventing kidneytransplant failure by screening for antibodies
Imlifidase as a desensitisation treatment to enable kidneytransplant in highly sensitised adult transplant candidates 1 Medical Services Advisory Committee (MSAC) Public Summary Document Application No. 1732 – Imlifidase in the desensitisation treatment of highly sensitised adult kidneytransplant patients with a positive crossmatch against an available deceased donor or living donor, who , cost-effectiveness and total cost, MSAC did not support public funding of imlifidase as desensitisation treatment of highly sensitised (HS) adult kidneytransplant patients with a positive crossmatch against an available deceased donor (DD) or living donor (LD) who are unlikely to be transplanted under current kidney allocation systems, with a calculated panel-reactive antibody (cPRA) of 95
Incompatible living-donor kidneytransplantation (an update) Trasplante renal de donante vivo incompatible (actualización) | Servicio de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA) TwitterRssServicio de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA)La misión del Servicio de Evaluación de Tecnologías Sanitaria AETSA es apoyar la toma de decisiones relacionadas con el uso * Contacto * Producción * Trabajos en marcha * Producción científica * Trabajo en red * Red de agencias del SNS (RedETS). * EUnetHTA-JA3 * Euroscan * INAHTA * Actividades * Formación * Colabora con nosotros * Noticias * Eventos Trasplante renal de donante vivo incompatible (actualización)Volver al buscadorIncompatible living-donor kidneytransplantation
a deceased donor with whom they had a positive crossmatch. Key strengths Imlifidase is the first medicine licensed for desensitisation treatment of highly sensitised adult kidneytransplant patients with positive crossmatch against an available deceased donor.1 Imlifidase rapidly reduces DSA leading to a conversion to a negative crossmatch, which facilitates renaltransplantation in highly sensitised Imlifidase (Idefirix) - adult kidneytransplant patients Published 12 September 2022 1 SMC2445 imlifidase 11mg powder for concentrate for solution for infusion (Idefirix®) Hansa Biopharma AB 08 July 2022 (Issued 05 August 2022) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidneytransplant recipients. Kidneytransplantation is the preferred management for patients with end-stage kidney disease (ESKD). However, it is often complicated by worsening or new-onset diabetes. The safety and efficacy of glucose-lowering agents after kidneytransplantation is largely unknown. This is an update of a review first published in 2017. To evaluate the efficacy and safety of glucose-lowering agents for treating pre-existing and new onset diabetes in people who have undergone kidneytransplantation. We searched the Cochrane Kidney and Transplant Register of Studies up to 16 January 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register
Relationship between volume of services and quality of treatment outcome for kidneytransplantations - Rapid report 1 Translation of Chapters 1 to 7 of the rapid report V19-02 Zusammenhang zwischen Leistungsmenge und Qualität des Behandlungsergebnisses bei Nierentransplantation (inklusive Lebendspende) (Version 1.0; Status: 24 April 2020 for kidneytransplantations (including living donations)1 Extract of rapid report V19-02 Version 1.0 Relationship volume of services and quality for kidneytransplantations 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Relationship between volume of services and quality of treatment
. Kasiske BL, Zeier MG, Craig JC, Ekberg H, Garvey CA, Green MD et al. KDIGO clinical practice guideline for the care of kidneytransplant recipients. Am J Transplant 2009;9:30−32. 3. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C et al. Lack of benefit of early protocol biopsies in renaltransplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007;7:2538−2545. 4 /05/service-spec-adult-kidney-transplant-service.pdf CEff 040121 13 V1 Final Appendix A Minimal dataset for reporting of renaltransplant biopsies Surname: ..............................Forenames:.............................Date of birth: ..................Sex:............ Hospital
RenalTransplant Dysfunction ACR Appropriateness Criteria® 1 RenalTransplant Dysfunction American College of Radiology ACR Appropriateness Criteria® RenalTransplant Dysfunction Variant 1: Adult. Renaltransplant dysfunction. Initial imaging. Procedure Appropriateness Category Relative Radiation Level US duplex Doppler kidneytransplant Usually Appropriate O US pelvis Usually Not Appropriate Not Appropriate ☢☢☢☢ ACR Appropriateness Criteria® 5 RenalTransplant Dysfunction Variant 5: Adult. Renaltransplant dysfunction. US unremarkable or indeterminate. Next imaging study. Procedure Appropriateness Category Relative Radiation Level Image-guided biopsy kidney Usually Appropriate Varies US duplex Doppler kidneytransplant Usually Not Appropriate O US pelvis Usually Not Appropriate O US pelvis with IV
citrate concentrations [43]. Citrate can complex calcium ions and increase their solubility. Thus, kidney stones in hypocitraturia are mostly calcium-containing stones. Hypocitraturia is more prominent after renaltransplantation and predisposes for post-transplant nephrolithiasis [44]. NEPHROLITHIASIS AMONG KIDNEYTRANSPLANT RECIPIENTSPrevalenceA retrospective cohort study involving 42096 kidney hypocalciuria and an increased urine volume are relatively common in kidneytransplant recipients, this may explain the lower observed rates of nephrolithiasis after renaltransplantation. The underlying pathophysiological mechanism leading to hypocitraturia is unclear, with several potential hypothetical mechanisms; kidneytransplant recipients are prone to metabolic acidosis due to allograft function
Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidneytransplant recipients: An analysis of the Organ Procurement and Transplantation Network database. Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidneytransplant recipients and is associated with a risk of post-transplant lymphoproliferative
Long-term Double-J stenting is superior to short-term Single-J stenting in kidneytransplantation. Urological complications after kidneytransplantation, due to the ureteroneocystostomy, are associated with significant morbidity, prolonged hospital stay and even mortality. Ureteral stents can minimize the number of complications but are not consistently used, as previous studies were retrospective in nature. We aim to prospectively determine the most effective stenting approach. We performed a non-blinded single-centre randomised controlled trial in an academic hospital. Kidneytransplant recipients were randomised to either a Single-J stent or a Double-J stent, removed according to respective protocols. Primary outcome was PCN placement within six months. Secondary outcomes encompassed
A structured, home-based exercise programme in kidneytransplant recipients (ECSERT): A randomised controlled feasibility study. Cardiometabolic diseases are a major cause of morbidity and mortality in kidneytransplant recipients (KTR) due to clustering of traditional and non-traditional risk factors including poor physical fitness and physical inactivity. Exercise may mitigate the risk
Early economic evaluation of chelation therapy in kidneytransplant recipients with high-normal lead. Kidneytransplant recipients (KTR) with high-normal lead have a higher risk of graft failure (GF). Clinically, chelation therapy using meso-2,3-dimercaptosuccinic acid (DMSA) removes lead. Despite the proposal that chelation therapy can prevent GF through lead removal, evidence is lacking
Taming the transplant troll: Exploring racial and ethnic disparities in cytomegalovirus infection among kidneytransplant patients. Cytomegalovirus (CMV) infection poses a significant risk to kidneytransplant recipients. This study investigated CMV disease incidence, outcomes, and management challenges in racial and ethnic minority populations following kidneytransplantation. This single -center, mixed-methods study included a retrospective cohort analysis of kidneytransplant recipients (n = 58) and qualitative surveys of healthcare providers. Patients were categorized as minorities (n = 49) or non-Hispanic whites (n = 9). The primary outcome was CMV disease incidence. Secondary outcomes included graft failure, mortality, and identification of management barriers. The cumulative
The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After KidneyTransplantation : A Retrospective Cohort Study. Prior studies indicate that 1% to 4% of Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R-) kidneys develop posttransplant lymphoproliferative disorder (PTLD). However, these estimates are based on limited data that lack granularity. To determine the associations between pretransplant EBV D+/R- and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival among adult kidneytransplant recipients. Retrospective cohort study. Two large U.S. transplant centers. Epstein-Barr virus D+/R- and EBV R+ recipients matched 1:3 on donor, recipient, and transplant characteristics between